Compare CSPI & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | PEPG |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | 123 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 121.7M |
| IPO Year | 1994 | 2022 |
| Metric | CSPI | PEPG |
|---|---|---|
| Price | $9.81 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.17 |
| AVG Volume (30 Days) | 9.9K | ★ 883.1K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 75.00 | 25.61 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $58,730,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $233.13 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.55 | $1.01 |
| 52 Week High | $15.49 | $7.80 |
| Indicator | CSPI | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 35.85 |
| Support Level | $9.72 | $1.32 |
| Resistance Level | $10.59 | $5.37 |
| Average True Range (ATR) | 0.58 | 0.15 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 65.32 | 24.11 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.